To evaluate the effect of GSK-3685032 on ORF1p expression in ES-2 cells, results showed that GSK-3685032 robustly induced ORF1p expression within 4 days without appreciable DNA damage.
NPJ Precis Oncol. 2025 Mar 6;9(1):62
12Z
100 nM, 500 nM, 1 μM, or 5 μM
1, 2, or 4 days
To evaluate the effect of GSK-3685032 on ORF1p expression in 12Z cells, results showed that GSK-3685032 robustly induced ORF1p expression within 4 days without appreciable DNA damage.
NPJ Precis Oncol. 2025 Mar 6;9(1):62
hEM3
100 nM, 500 nM, 1 μM, or 5 μM
1, 2, or 4 days
To evaluate the effect of GSK-3685032 on ORF1p expression in hEM3 cells, results showed that GSK-3685032 robustly induced ORF1p expression within 4 days without appreciable DNA damage.
NPJ Precis Oncol. 2025 Mar 6;9(1):62
KRAS mutant NSCLC cells
10 nM
Evaluate the effect of DNMT1 inhibition on 3D growth, results showed similar to UHRF1 knockout, significantly inhibiting spheroid growth
Nat Commun. 2023 Jul 5;14(1):3966
MDS-L cells
1 µM
4 days
To assess the sensitivity of MDS-L cells to GSK-3685032, results showed no significant difference in sensitivity between TOPORS-edited and control cells.
Nat Commun. 2024 Aug 28;15(1):7360
GSK-3685032 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
MV4–11 and SKM-1 subcutaneous xenograft models
Subcutaneous injection
1 to 45 mg/kg
Twice daily for ≥4 weeks
To evaluate the in vivo efficacy and tolerability of GSK3685032 in AML models
搜索
